Literature DB >> 15214512

Single photon emission computed tomography (SPECT) in obsessive-compulsive disorder before and after treatment with inositol.

P D Carey1, J Warwick, B H Harvey, D J Stein, S Seedat.   

Abstract

Inositol, a glucose isomer and second messenger precursor, regulates numerous cellular functions and has demonstrated efficacy in obsessive-compulsive disorder (OCD) through mechanisms that remain unclear. The effect of inositol treatment on brain function in OCD has not been studied to date. Fourteen OCD subjects underwent single photon emission computed tomography (SPECT) with Tc-99m HMPAO before and after 12 weeks of treatment with inositol. Whole brain voxel-wise SPM was used to assess differences in perfusion between responders and nonresponders before and after treatment as well as the effect of treatment for the group as a whole. There was 1) deactivation in OCD responders relative to nonresponders following treatment with inositol in the left superior temporal gyrus, middle frontal gyrus and precuneus, and the right paramedian post-central gyrus; 2) no significant regions of deactivation for the group as a whole posttreatment; and 3) a single cluster of higher perfusion in the left medial prefrontal region in responders compared to nonresponders at baseline. Significant reductions in the YBOCS and CGI-severity scores followed treatment. These data are only partly consistent with previous functional imaging work on OCD. They may support the idea that inositol effects a clinical response through alternate neuronal circuitry to the SSRIs and may complement animal work proposing an overlapping but distinct mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15214512     DOI: 10.1023/b:mebr.0000027423.34733.12

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  38 in total

Review 1.  How accurately can we image inositol lipids in living cells?

Authors:  T Balla; T Bondeva; P Várnai
Journal:  Trends Pharmacol Sci       Date:  2000-07       Impact factor: 14.819

2.  Septal GABAergic and hippocampal cholinergic systems interact in the modulation of anxiety.

Authors:  A Degroot; D Treit
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

3.  Inositol treatment of autism.

Authors:  J Levine; A Aviram; A Holan; A Ring; Y Barak; R H Belmaker
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

4.  Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Patients treated with clomipramine.

Authors:  C Benkelfat; T E Nordahl; W E Semple; A C King; D L Murphy; R M Cohen
Journal:  Arch Gen Psychiatry       Date:  1990-09

5.  Cerebral blood flow in obsessive-compulsive patients with major depression: effect of treatment with sertraline or desipramine on treatment responders and non-responders.

Authors:  R Hoehn-Saric; T E Schlaepfer; B D Greenberg; D R McLeod; G D Pearlson; S H Wong
Journal:  Psychiatry Res       Date:  2001-11-30       Impact factor: 3.222

6.  Neural correlates of clinical symptoms and cognitive dysfunctions in obsessive-compulsive disorder.

Authors:  Jun Soo Kwon; Jae-Jin Kim; Dong Woo Lee; Jae Sung Lee; Dong Soo Lee; Myung-Sun Kim; In Kyoon Lyoo; Maeng Je Cho; Myung Chul Lee
Journal:  Psychiatry Res       Date:  2003-01-20       Impact factor: 3.222

7.  Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder.

Authors:  A Palatnik; K Frolov; M Fux; J Benjamin
Journal:  J Clin Psychopharmacol       Date:  2001-06       Impact factor: 3.153

8.  Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression.

Authors:  Sanjaya Saxena; Arthur L Brody; Matthew L Ho; Narineh Zohrabi; Karron M Maidment; Lewis R Baxter
Journal:  Am J Psychiatry       Date:  2003-03       Impact factor: 18.112

9.  Functional anatomy of obsessive-compulsive phenomena.

Authors:  P K McGuire; C J Bench; C D Frith; I M Marks; R S Frackowiak; R J Dolan
Journal:  Br J Psychiatry       Date:  1994-04       Impact factor: 9.319

10.  Localized functional neurochemical marker abnormalities in dorsolateral prefrontal cortex in pediatric obsessive-compulsive disorder.

Authors:  Aileen Russell; Bernadette Cortese; Elisa Lorch; Jennifer Ivey; S Preeya Banerjee; Gregory J Moore; David R Rosenberg
Journal:  J Child Adolesc Psychopharmacol       Date:  2003       Impact factor: 2.576

View more
  4 in total

1.  Association of Myoinositol Transporters with Schizophrenia and Bipolar Disorder: Evidence from Human and Animal Studies.

Authors:  Marquis P Vawter; Abdul Rezzak Hamzeh; Edgar Muradyan; Olivier Civelli; Geoffrey W Abbott; Amal Alachkar
Journal:  Mol Neuropsychiatry       Date:  2019-08-08

2.  Relevance of orbitofrontal neurochemistry for the outcome of cognitive-behavioural therapy in patients with obsessive-compulsive disorder.

Authors:  Bartosz Zurowski; Andreas Kordon; Wolfgang Weber-Fahr; Ulrich Voderholzer; Anne Katrin Kuelz; Tobias Freyer; Karina Wahl; Christian Büchel; Fritz Hohagen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-17       Impact factor: 5.270

3.  Post-operative Changes of Cerebral Glucose Metabolism in Patients with Lumbar Spinal Stenosis with Pre-operative Anxiety: Statistical Parametric Mapping Analysis of F-18 FDG Brain PET.

Authors:  Seong-Jang Kim; Kuen Tak Suh; Jeung Il Kim; Jong Min Lim; Tae Sik Goh; Jung Sub Lee
Journal:  Asian Spine J       Date:  2011-05-02

4.  Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram.

Authors:  Paul D Carey; James Warwick; Dana J H Niehaus; Geoffrey van der Linden; Barend B van Heerden; Brian H Harvey; Soraya Seedat; Dan J Stein
Journal:  BMC Psychiatry       Date:  2004-10-14       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.